Home › Colorectal Cancer
Colorectal Cancer clinical trials recruiting in the U.S.
338 studies for Colorectal Cancer are recruiting participants at sites across the United States.
Colorectal cancer starts in the colon or rectum. It may not cause symptoms at first. Screening tests can help find it early, when treatment is most effective.
Cities with the most studies
- Houston, TX102 studies
- New York City, NY77 studies
- Nashville, TN68 studies
- Boston, MA63 studies
- Los Angeles, CA59 studies
- Arlington, VA52 studies
- St. Louis, MO49 studies
- San Antonio, TX46 studies
- Philadelphia, PA44 studies
- Grand Rapids, MI40 studies
- Baldwin Park, CA38 studies
- Seattle, WA34 studies
- Dallas, TX33 studies
- Tampa, FL33 studies
- Pittsburgh, PA32 studies
- Aurora, CO32 studies
- Chicago, IL32 studies
- Queens, NY31 studies
- Baltimore, MD31 studies
- Washington, DC29 studies
- Rochester, MN29 studies
- Atlanta, GA29 studies
- Portland, OR28 studies
- Durham, NC28 studies
- Jacksonville, FL27 studies
- Detroit, MI27 studies
- Phoenix, AZ25 studies
- Cleveland, OH24 studies
- Edison, NJ24 studies
- San Diego, CA24 studies
- Denver, CO23 studies
- Ann Arbor, MI23 studies
- Columbus, OH23 studies
- Santa Monica, CA22 studies
- Madison, WI22 studies
- Oklahoma City, OK22 studies
- New Haven, CT21 studies
- Cincinnati, OH21 studies
- Salt Lake City, UT21 studies
- Omaha, NE19 studies
By state
- Alabama13 studies
- Alaska4 studies
- Arizona54 studies
- Arkansas14 studies
- California136 studies
- Colorado56 studies
- Connecticut24 studies
- Delaware9 studies
- District of Columbia17 studies
- Florida99 studies
- Georgia38 studies
- Hawaii5 studies
- Idaho7 studies
- Illinois51 studies
- Indiana27 studies
- Iowa14 studies
- Kansas19 studies
- Kentucky20 studies
- Louisiana18 studies
- Maine4 studies
- Maryland47 studies
- Massachusetts63 studies
- Michigan73 studies
- Minnesota45 studies
- Mississippi6 studies
- Missouri57 studies
- Montana6 studies
- Nebraska23 studies
- Nevada9 studies
- New Hampshire6 studies
- New Jersey35 studies
- New Mexico8 studies
- New York98 studies
- North Carolina44 studies
- North Dakota7 studies
- Ohio62 studies
- Oklahoma22 studies
- Oregon29 studies
- Pennsylvania69 studies
- Rhode Island5 studies
- South Carolina13 studies
- South Dakota10 studies
- Tennessee75 studies
- Texas145 studies
- Utah36 studies
- Vermont3 studies
- Virginia76 studies
- Washington47 studies
- West Virginia5 studies
- Wisconsin36 studies
- Wyoming3 studies
Recently updated studies
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07551596Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05803382A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07659795A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07578571Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RecruitingPhase 1/2Mentions payment for participants
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT06149481Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07222800Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05482893A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07525206A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06820463A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06662786Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06004245Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07277270A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06428409Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07271355A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06750094A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05379595A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06663319A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT05863195Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07221357From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.